NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of intellectual property protection surrounding the Company's T-regulatory cell ("Treg") program with the grant of Japanese Patent Number 5409827 titled "Methods for the Isolation and Expansion of Cord Blood Derived T Regulatory Cells." This grant further expands the scope and reach of NeoStem's Treg patent estate internationally.
Through its Treg program, NeoStem is developing therapies that restore immune balance by enhancing regulatory T cell number and function. NeoStem's novel approach is being advanced by collaborations with leading research teams in the field of T cell therapy, including a collaboration with the University of California, San Francisco, and the laboratories of Drs. Jeffrey Bluestone and Qizhi Tang. NeoStem has a broad patent estate covering the Treg program, including over 30 issued patents and patent applications in U.S. and major international markets.
In November 2013, Japan enacted the Regenerative Medicine Law and passed revisions to the Pharmaceutical Affairs Law, providing opportunities to accelerate the development of regenerative medicines in Japan."We are excited to have received this patent issuance and about the recent changes in Japan which signal Japan's commitment to regenerative medicine. We look forward to exploring opportunities in Japan within the new regulatory framework to develop our regenerative medicine products in Japan and to bringing these important products to the market to meet the health needs of the Japanese people," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. In addition, these new Japanese regulations should be meaningful in allowing NeoStem to accelerate time to market in Japan for its cardiovascular disease program, for which NeoStem has already been granted related patent protection in Japan, should the Company pursue clinical development there.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV